1. Home
  2. INGN vs GNLX Comparison

INGN vs GNLX Comparison

Compare INGN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$7.20

Market Cap

186.8M

Sector

Health Care

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.74

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
GNLX
Founded
2001
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.8M
202.4M
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
INGN
GNLX
Price
$7.20
$2.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$11.00
$19.75
AVG Volume (30 Days)
156.7K
140.7K
Earning Date
02-24-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$347,028,000.00
N/A
Revenue This Year
$8.04
N/A
Revenue Next Year
$8.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.68
N/A
52 Week Low
$5.70
$1.99
52 Week High
$12.91
$8.54

Technical Indicators

Market Signals
Indicator
INGN
GNLX
Relative Strength Index (RSI) 59.28 21.34
Support Level $6.53 $3.32
Resistance Level $7.46 $4.99
Average True Range (ATR) 0.18 0.35
MACD 0.08 -0.10
Stochastic Oscillator 72.04 4.07

Price Performance

Historical Comparison
INGN
GNLX

About INGN Inogen Inc

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: